Advances in Targeted Therapies for Triple-Negative Breast Cancer

被引：72

作者：

McCann, Kelly E. ^{[1
]}

Hurvitz, Sara A. ^{[1
]}

McAndrew, Nicholas ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, 2336 Santa Monica,Suite 304, Los Angeles, CA 90404 USA

来源：

DRUGS | 2019年 / 79卷 / 11期

关键词：

SACITUZUMAB GOVITECAN; 1ST-LINE THERAPY; DOUBLE-BLIND; PARP; INHIBITOR; PALBOCICLIB; FULVESTRANT; SUBTYPES; AKT; IMMUNOTHERAPY;

D O I：

10.1007/s40265-019-01155-4

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

While the outcomes for patients diagnosed with hormone receptor positive (HR+) and/or human epidermal growth factor receptor 2-positive (HER2+) breast cancers have continued to improve with the development of targeted therapies, the same cannot be said yet for those affected with triple-negative breast cancer (TNBC). Currently, the mainstay of treatment for the 10- 15% of patients diagnosed with TNBC remains cytotoxic chemotherapy, but it is hoped that through an enhanced characterization of TNBC biology, this disease will be molecularly delineated into subgroups with targetable oncogenic drivers. This review will focus on recent therapeutic innovations for TNBC, including poly-ADP-ribosyl polymerase (PARP) inhibitors, phosphoinositide 3-kinase (PI3K) pathway inhibitors, immune checkpoint inhibitors, and cyclin-dependent kinase (CDK) inhibitors.

引用

页码：1217 / 1230

页数：14

共 67 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2]

André F, 2018, ANN ONCOL, V29, P709

[3]

[Anonymous], J CLIN ONCOL S

[4] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Mayer, I. A. ;

Vahdat, L. T. ;

Tolaney, S. M. ;

Isakoff, S. J. ;

Diamond, J. R. ;

O'Shaughnessy, J. ;

Moroose, R. L. ;

Santin, A. D. ;

Abramson, V. G. ;

Shah, N. C. ;

Rugo, H. S. ;

Goldenberg, D. M. ;

Sweidan, A. M. ;

Iannone, R. ;

Washkowitz, S. ;

Sharkey, R. M. ;

Wegener, W. A. ;

Kalinsky, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) :741-751

[5] Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer [J].

Bardia, Aditya ;

Mayer, Ingrid A. ;

Diamond, Jennifer R. ;

Moroose, Rebecca L. ;

Isakoff, Steven J. ;

Starodub, Alexander N. ;

Shah, Nikita C. ;

O'Shaughnessy, Joyce ;

Kalinsky, Kevin ;

Guarino, Michael ;

Abramson, Vandana ;

Juric, Dejan ;

Tolaney, Sara M. ;

Berlin, Jordan ;

Messersmith, Wells A. ;

Ocean, Allyson J. ;

Wegener, William A. ;

Maliakal, Pius ;

Sharkey, Robert M. ;

Govindan, Serengulam V. ;

Goldenberg, David M. ;

Vahdat, Linda T. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2141-+

[6] Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer [J].

Burstein, Matthew D. ;

Tsimelzon, Anna ;

Poage, Graham M. ;

Coyington, Kyle R. ;

Contreras, Alejandro ;

Fuqua, Suzanne A. W. ;

Sayage, Michelle I. ;

Osborne, C. Kent ;

Hilsenbeck, Susan G. ;

Chang, Jenny C. ;

Mills, Gordon B. ;

Lau, Ching C. ;

Brown, Powel H. .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1688-1698

[7] The phosphoinositide 3-kinase pathway [J].

Cantley, LC .

SCIENCE, 2002, 296 (5573) :1655-1657

[8] New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].

Cantley, LC ;

Neel, BG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245

[9] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers [J].

Cardillo, Thomas M. ;

Govindan, Serengulam V. ;

Sharkey, Robert M. ;

Trisal, Preeti ;

Arrojo, Roberto ;

Liu, Donglin ;

Rossi, Edmund A. ;

Chang, Chien-Hsing ;

Goldenberg, David M. .

BIOCONJUGATE CHEMISTRY, 2015, 26 (05) :919-931

[10] Oncology Meets Immunology: The Cancer-Immunity Cycle [J].

Chen, Daniel S. ;

Mellman, Ira .

IMMUNITY, 2013, 39 (01) :1-10

← 1 2 3 4 5 6 7 →